PWE-025 Assessing the Percent of Days Linaclotide Improved Abdominal Symptoms and Stool Frequency in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): Pooled Analysis of 2 Phase 3 Trials

Abstract

IntroductionLinaclotide (LIN), a minimally absorbed guanylate cyclase C agonist (GCCA), improved abdominal symptoms and bowel movement (BM) frequency in patients (pts) with IBS-C in 2 Phase 3 trials. This post-hoc...